Treatment

Placebo tablets LFM, PLAQUENIL 200 mg compresse rivestite clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic confirmatory (Phase III)
A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc
This study is looking at whether adding hydroxychloroquine (Plaquenil) to usual treatment helps people with early systemic sclerosis. Researchers want to see if it improves symptoms and is safe, compared to a dummy pill, over 52 weeks.
For: Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG · n°65-S.O. n°15 - 18/03/2017), characterized by immunological, vascular and fibrotic · abnormalities. The estimated incidence is 18 to 20 cases per million population year
Italy